drugset / Trial / NCT03619616
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.
Timeline
- Start
- 2018-07-16
- Primary completion
- 2019-06-28
- Completion
- 2019-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZSP1603 | Unknown | 7.5 mg | Oral |
| Subject | ZSP1603 | Unknown | 12.5 mg | Oral |
| Subject | ZSP1603 | Unknown | 25 mg | Oral |
| Subject | ZSP1603 | Unknown | 50 mg | Oral |